You are correct. The total market for Breast Cancer Therapeutics is projected by this firm to be USD $32B by 2026.
https://www.mordorintelligence.com/industry-reports/breast-cancer-therapeutics-market
Versus total Doxorubicin market USD $1.38B by 2024 (from link you posted). Now only a fraction of this market, albeit a large fraction would be for Breast Cancer.
Here's earlier analysis I did of the usage of Doxorubicin in HER- and HER+ breast cancer chemotherapy regimens. The proportion across the combined group is 60% ( 12 of 20 regimens use Doxorubicin ).
https://www.cancertherapyadvisor.co...ns/breast-cancer-invasive-treatment-regimens/
This is why I think Bisantrene with its heart safety will create a wedge into the existing market for Breast Cancer and lead to the total market value for Breast Cancer significantly expanding ( by around 45% based on estimate of peak sales for Bisantrene for Pillar 2 and market research firm estimates of the size of the Breast Cancer therapeutics market in 2026). Doxorubicin is the dominant drug used in Breast Cancer chemotherapy ... so what happens when something much, much safer for the heart comes along.
- Forums
- ASX - By Stock
- RAC
- Pillar 1 - FTO (new thread)
Pillar 1 - FTO (new thread), page-368
-
- There are more pages in this discussion • 2,657 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.53 |
Change
-0.060(3.77%) |
Mkt cap ! $260.7M |
Open | High | Low | Value | Volume |
$1.59 | $1.59 | $1.53 | $83.43K | 53.65K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20575 | $1.53 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.57 | 300 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20575 | 1.530 |
1 | 500 | 1.525 |
1 | 2750 | 1.510 |
4 | 14647 | 1.505 |
7 | 18242 | 1.500 |
Price($) | Vol. | No. |
---|---|---|
1.570 | 300 | 1 |
1.590 | 10776 | 3 |
1.600 | 23400 | 1 |
1.650 | 17029 | 2 |
1.690 | 6570 | 3 |
Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online